Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ORION trial: what clinicians have said so far
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
- NCT03775486 ↗
- Active, not recruiting
- AstraZeneca
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ORION (stage IV non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ORION so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer NSCLC
- Interventions
- Durvalumab; Placebo for Olaparib; Olaparib; Nab-paclitaxel+carboplatin; Gemcitabine+carboplatin; Pemetrexed+carboplatin; Gemcitabine+cisplatin; Pemetrexed+cisplatin
- Arms
- Durvalumab/Olaparib Combination Therapy · Experimental
- Durvalumab Monotherapy · Experimental
- Enrollment
- 401
- Primary outcomes
- Progression-free Survival
- Sponsor
- AstraZeneca
- Start
- Dec 21, 2018
- Primary completion
- Jan 11, 2021
- Results posted
- Yes
- Registry record
- NCT03775486 · updated Sep 11, 2026
Publications
linked from the registry- Ahn MJ, Bondarenko I, Kalinka E, Cho BC, Sugawara S, Galffy G, Shim BY, Kislov N, Nagarkar R, Demedts I, Gans SJM, Mendoza Oliva D, Stewart R, Lai Z, Mann H, Shi X, Hussein M. Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study. J Thorac Oncol. 2023 Nov;18(11):1594-1606. doi: 10.1016/j.jtho.2023.06.013. Epub 2023 Jun 29. PubMed 37390980